Research

Hormonal

GLP-1 receptor agonists slow renal disease progression and reduce albuminuria in patients with diabetic kidney disease, although evidence is less robust than for SGLT2 inhibitors.

If you have diabetic kidney disease, GLP-1 receptor agonists may help slow kidney damage and reduce protein in your urine. While there is less data on their kidney benefits compared to SGLT2 inhibitors, they are still considered valuable. Discuss with your doctor if they are appropriate for you, especially if you have cardiovascular risks.

GoodQualifiesHIGH confidence
Although fewer studies have specifically investigated GLP-1 receptor agonists in patients with kidney disease, existing evidence underscores their potential to slow renal disease progression, reduce albuminuria, and improve clinically relevant outcomes.
Gabriel LC Santos et al. · World Journal of Diabetes · 2025

Why this rating

Based on existing evidence and trials, but explicitly noted as having 'fewer studies' than SGLT2i.

Source

Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease

Gabriel LC Santos et al. · World Journal of Diabetes · 2025

DOI 10.4239/wjd.v16.i6.104706

narrative_reviewCited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →